Regulation of Proliferation of Human Colonic Subepithelial Myofibroblasts by Mediators Important in Intestinal Inflammation

Timothy M. Jobson, Charlotte K. Billington, and Ian P. Hall
Division of Therapeutics, University Hospital, Queen’s Medical Centre, Nottingham NG7 2UH, United Kingdom

Abstract

An increase in myofibroblast number may be necessary for wound healing but may also lead to postinflammatory scar- ring. We have, therefore, studied the role of mediators im- portant in inflammatory bowel disease in regulating prolif- eration of human colonic myofibroblasts. Using primary cultures of these cells, we have shown increases in [3H]thy- midine incorporation in response to platelet-derived growth factor (EC50 = 14 ng/ml), basic fibroblast growth factor (EC50 = 2.2 ng/ml), and epidermal growth factor (EC50 = 1.1 ng/ml). Coulter counting of cell suspensions demonstrated increases in cell number with these growth factors along with insulin-like growth factor-I and -II. In addition the proinflammatory cytokines IL-1β and TNF-α produced increases in [3H]thymidine incorporation. IL-1β and plate- let-derived growth factor together produced an increase in [3H]thymidine greater than either agonist alone; this effect was not, however, seen when we examined changes in cell numbers. Finally, we demonstrate a mechanism whereby these responses may be downregulated: vasoactive intestinal peptide (1 μM) elevates cyclic AMP in these cells 4.2-fold over control and produces a dose-related inhibition of plate- let-derived growth factor–driven proliferation with a maxi- mum inhibition of 33% at 1 μM. (J. Clin. Invest. 1998. 101: 2650–2657.) Key words: inflammatory bowel disease • fibrosis • growth factors • cytokines • vasoactive intestinal peptide

Introduction

Myofibroblast proliferation is seen in response to inflamma- tion in many tissues regardless of the aetiology of the insult. Where damage to an epithelial layer occurs, for example in the skin, proliferation of underlying myofibroblasts may be important for wound healing. It is also recognized, however, that excess myofibroblasts persisting beyond the inflammatory insult may be a risk factor for scarring and pathological remodeling of the tissue (1, 2). In the colon, these processes may be important in the pathophysiology of the chronic inflammatory pro- cess in inflammatory bowel diseases. In these conditions, ulceration occurs and subepithelial cell growth may therefore be required for resolution of the damage. In longstanding inflam- mation, however, marked changes in the lamina propria archi- tecture are seen with destruction of epithelial crypts and excess matrix production (3). The cause of this remodeling is un- known, but excess myofibroblast number and, consequently, excess collagen production is a potential aetiological factor.

A number of peptides important in the pathogenesis of ul-cerative colitis have potential to regulate myofibroblast num- ber. Growth factors such as PDGF-BB, basic fibroblast growth factor (bFGF), and EGF are found in the colonic mucosa (4, 5), and are mitogens for myofibroblast-like cells derived from other tissues. IGF-I and IGF-II have been shown to be upregu- lated in animal models of chronic inflammation (6) and have been shown to promote survival of other mesenchymal cells (7). The proinflammatory cytokines IL-1β (8) and TNF-α are upregulated in inflammation of the colon (9), and are thought to play a key role in initiating the inflammatory response (10). The proinflammatory cytokine IL-6 is upregulated in ulcer- ative colitis (9), as is the antiinflammatory cytokine IL-10 (11), which has a key immunomodulatory role in inflammatory bowel disease (12). There is good evidence that these peptides may be produced locally in the colonic mucosa from either macrophages or other leukocytes in close proximity to myofi- broblasts, and that tissue levels may be significantly altered during inflammation.

The role played by neuropeptides in inflammatory bowel disease is unclear, but vasoactive intestinal peptide (VIP) has potentially important immunomodulatory functions (13) and is produced by both nerve endings (14) and inflammatory cells in the lamina propria (15). In addition, eosinophils present in the normal mucosa may secrete VIP. Because the VIP recep- tor is positively coupled to adenylate cyclase and it is known that elevating cyclic AMP inhibits proliferation in other sys- tems (e.g., human airway smooth muscle cells; 16), VIP could potentially inhibit proliferative responses in subepithelial myofi- broblasts.

The factors that regulate intestinal myofibroblast numbers are unknown, but clearly long-term changes in cell number are likely to be important in remodeling of the mucosa. Cell culture models are a useful tool in understanding these processes, but, until recently, in vitro studies of human colonic myofi- broblasts have relied on the use of immortal cell lines (17), the growth characteristics of which are likely to be different from nontransformed cells. Studies on primary cultures of human intestinal smooth muscle cells have been performed for a limited number of mitogens (18, 19), and although these cells may be important in transmural inflammation and stricture develop- ment, they are unlikely to play a role in healing and remodel- ing in the subepithelial layers. A novel ex vivo model has re- cently been established that enables pure populations of subepithelial myofibroblasts from adult human intestinal mu-
cosa to be available (20). Using these cells, we have studied the role of mediators important in inflammatory bowel disease in driving or inhibiting colonic myofibroblast mitogenesis.

**Methods**

**Materials.** Sterile plasticware was from Costar (Cambridge, MA). All tissue culture materials and reagents were from Sigma Chemical Co. (St. Louis, MO), except for penicillin, streptomycin and amphotericin (pen-strep-fungizone), and PBS, which were from Gibco BRL (Gaithersburg, MD), and FCS, which was from Advanced Protein Products (Brierley Hill, UK). Recombinant human growth factors were from Peprotech EC Ltd. (London, UK), recombinant human IL-1β was from Genzyme (Cambridge, MA), and human VIP was from Calbiochem (Nottingham, UK). Radiochemicals: [3H]thymidine (specific activity: 81.0 Ci/mmol), 35C-labeled cyclic AMP (26.8 Ci/mmol), and [3H]adenine (52.3 Ci/mmol) were obtained from Amersham International (Amersham, Bucks, UK).

**Culture of human colonic myofibroblasts.** Primary cultures of myofibroblasts were established as recently described (20). In brief, samples of human adult normal colonic mucosa obtained from resection specimens (> 5 cm from the tumor margin) from patients undergoing partial colectomy for carcinoma were separated from the underlying muscularis mucosae by microdissection. Mucosal strips were subsequently denuded of epithelial cells by sequential treatments with EDTA (21). It has previously been demonstrated that myofibroblasts will migrate through basement membrane pores during culture of deepithelialized mucosal samples. Lamina propria lymphocytes, macrophages, and eosinophils also migrate via basement membrane pores (21) and were, therefore, removed with frequent changes of media (RPMI/10% FCS). Colonies of myofibroblasts appeared after culture of denuded mucosal fragments for ~ 2 wk. These colonies grew to form a confluent monolayer over the subsequent 1–3 wk. At this stage, cells were harvested by incubating for 5–10 min in trypsin (0.5%/EDTA (5 mM) in PBS at 37°C followed by addition of whole growth medium, DME containing 15% FCS, glutamine (2 mM), penicillin G (100 u/ml), streptomycin (100 μg/ml), and amphotericin-B (0.25 μg/ml). Cells were then centrifuged at 275 g for 10 min and resuspended in growth medium. Cells were maintained in culture up to passage 12. In general, cells were grown in 75-cm² flasks and split 1:3 at each passage with trypsin/EDTA as described above. For experiments, cells were split from one flask to four 24-well plates and grown over 4–7 d.

**Phenotypic verification of human colonic myofibroblasts.** Verification of continuing myofibroblast phenotype was achieved by light, electron, and fluorescent microscopy. Phase contrast microscopy was performed using an Axiovert 10 (Zeiss, Oberkochen, Germany) microscope on confluent and subconfluent cultures of human colonic myofibroblasts. Electron microscopy was performed by fixing cells grown on a petri dish using glutaraldehyde and subsequent imaging of ultrathin sections. For immunofluorescence microscopy, cells were grown to confluence in eight-chamber slides (Nunc Inc., Naperville, IL), washed in PBS three times (5 min per wash), and fixed by incubation with permeafix (Orthodiagnostics, Amersham, UK) for 10 min. The presence or absence of cellular proteins was determined using the following mouse monoclonal antibodies: smooth muscle α-actin (A2547), vimentin (V6630), desmin (D1033), myosin (M7786), and fibroblast surface protein (F4771; all from Sigma Chemical Co.; all antibodies used at 1:20 dilution). Cells were incubated for 14–18 h with the relevant primary antibody diluted in blocking solution (PBS + 10% FCS), followed by further washing with rabbit anti-mouse IgG secondary antibody conjugated to fluorescein isothiocyanate for 1 h. Cells were then viewed using a Nikon Diaphot 300 microscope (Melville, NY) under ultraviolet light and photographed. [3H]Thymidine incorporation. Subconfluent cultures (70–90%) of myofibroblasts in 24-well plates were washed and then incubated in DME containing 0.2% FCS, PSF, and glutamine for 24 h to growth arrest cells. Agonists were then added for 24–40 h as appropriate. [3H]Thymidine (1 μCi/well) was added for the final 16 h of the incubation. At the end of this period, the supernatant was aspirated and cells were washed twice with PBS before being fixed with methanol (100%)/glacial acetic acid (3:1) for at least 1 h at room temperature. Two further washes with methanol/water (4:1) were performed before lysing cells with 1 ml of 1 M NaOH (22). 900 μl of the supernatant was transferred to a scintillation vial along with 10 ml scintillation fluid (Packard, Meriden, CT) and counted on an LKB scintillation counter (efficiency 30%), results being expressed as disintegrations per minute or as fold stimulation over control.

**Determination of cell number.** Cells grown in 24-well plates were washed twice with PBS before being incubated for 10 min at 37°C with trypsin/EDTA. Cells were harvested by gentle but repeated re-suspension with a pipette and transferred to 10 ml Isoton (Coulter Electronics, Luton, UK) and counted on a Coulter counter using a lower size limit of 15 μm. This lower size limit was chosen after preliminary experiments demonstrating that the myofibroblasts have a diameter in suspension of 20–30 μm, and that a lower limit of < 15 μm leads to inclusion of cell debris in the counts.

**Determination of cyclic AMP responses.** Intracellular accumulation of cyclic AMP was determined using methods previously described in human airway myocyte cultures (23). In brief, confluent cultures of human colonic myofibroblasts were incubated in Hanks/Hepes buffer (HBSS without NaHCO₃; Gibco BRL) 48.8 g and Heps 26 g/5 liters, pH 7.4) with 2 μCi/well [3H]adenine for 3 h at 37°C. At the end of this time, cells were washed twice in 1 ml buffer alone and incubated for 20 min in 1 ml Hanks/Hepes to allow the cells to warm to 37°C. All experiments were performed without the addition of phosphodiesterase inhibitors. Agonists were then added and after 30 min, reactions were terminated by the addition of 50 μl of concentrated HCl. Cells were then stored at −20°C until rethawing for determination of [3H]-labeled cyclic AMP by column chromatography as previously described (24); a recovery label of [3H]-labeled cyclic AMP was added to each sample to correct for variations in recovery between columns. A 100-μl aliquot from each sample was taken before running on columns and counted for [3H] to correct for uptake of the [3H]adenine and variation in cell number.

**Statistical methods.** In general, results have been expressed as mean ± SEM. Results were compared with control using the paired Student’s t test and where multiple comparisons are made significance was confirmed by one-way ANOVA. For increases in cell number, a 95% confidence interval is calculated, a lower limit > 0 implying a significant increase (25).

**Results**

**Verification of myofibroblast phenotype.** Because this method of continued culture of intestinal subepithelial myofibroblasts is novel, we have taken steps to verify the phenotype of these cells after repeated passage. In subconfluent cultures, these cells took on a stellate morphology with fine processes extending from all cells (Fig. 1 a). On reaching confluence, the cells became more compact with typical swirls and hillocks. Another typical feature of myofibroblasts is the presence of longitudinally arranged bundles of microfilaments. Filamentous elements were clearly visible, using transmission electron microscopy (Fig. 1 c) of ultrathin sections of a monolayer grown on plastic tissue culture dishes.

Immunofluorescence studies revealed similar patterns of staining from passages 5 through 12, and also between donors. Cells stained positive for smooth muscle α-actin (Fig. 1, b and d), as well as the intermediate filament vimentin (Fig. 1 e). Only weak, nonspecific staining was seen with antibodies directed against desmin and fibroblast surface protein and no specific staining was seen for smooth muscle myosin. These
Figure 1. Phenotypic characterization of human colonic myofibroblasts. Cultured myofibroblasts seen by light microscopy (phase contrast) (a) and the same field stained for smooth muscle α-actin with FITC-conjugated secondary antibody and viewed under ultraviolet light (b). (c) Cross-section through a cultured cell as seen by electron microscopy with filaments clearly visible (arrow). (d and e) Immunofluorescence to smooth muscle α-actin and vimentin showing clear filamentous staining.
data are consistent with these cells being myofibroblasts with phenotypic features similar to myofibroblasts derived from other tissues (2, 26), and confirm that no significant phenotypic changes occur while the cells are maintained in continuous culture. Subsequent experiments were therefore performed on cells at passages 5–12.

**Growth factors increase uptake of [3H]thymidine.** PDGF-BB enhanced [3H]thymidine uptake into colonic myofibroblasts in a dose-related manner (Fig. 2). Of all the mitogens tested, it produced the largest increase in [3H]thymidine uptake in the myofibroblasts with a maximum fold stimulation over control of 7.0±0.5 (n = 4, P = 0.0004) in these experiments at a concentration of 100 ng/ml. The apparent EC₅₀ for this response was 14±1.2 ng/ml, although this may be an underestimate because the response did not reach a plateau over the (physiological) concentration range used in these experiments.

bFGF and EGF produced dose-related increases in [3H]thymidine uptake in human colonic myofibroblasts. The maximum stimulation of thymidine incorporation with bFGF was 3.0±0.06-fold over control (n = 4, P = 0.0004), whereas with EGF it was only 2.2±0.25 (n = 4, P = 0.03). Significant increases in [3H]thymidine incorporation were seen with both these mitogens over a range of physiological concentrations; the EC₅₀ for bFGF was 2.2±0.48 ng/ml (n = 4) and for EGF it was 1.1±0.17 ng/ml (n = 4). (Fig. 2). At 0.8 and 4 ng/ml, the mitogenic effect of EGF and bFGF was greater than that of PDGF-BB.

IGF-I and -II did not cause any significant change in [3H]thymidine uptake with concentrations within the probable physiological concentration range (0.1–20 ng/ml), although an increase was seen with 100 ng/ml to 3.4±0.17-fold over control (n = 4, P = 0.0005) for IGF-I, and 2.2±0.17-fold over control (n = 4, P = 0.003) for IGF-II (Fig. 2).

**Growth factors increase cell number.** As thymidine incorporation into the cell is only a marker for DNA synthesis, we studied changes in cell number over time. This was achieved by incubating cells for 72 h in 1% FCS and, in addition, growth factors and/or cytokines as appropriate. In preliminary experiments with 0–0.5% FCS, we found a decrease in the number of cells in control wells over the prolonged timecourse of the experiment; therefore, 1% FCS was routinely included in the medium in these experiments. Any increase in cell numbers is therefore compared with the changes seen in the counts obtained in the control wells at the end of the experimental period to control for variability in the response to FCS 1%. In some experiments, an initial cell count was taken at the beginning of the incubation period, allowing a calculation of change in cell number with control medium over the course of the experiment. This gave a mean increase of 14.8±2.2% (n = 4) over 72 h. In subsequent experiments where growth factors were added, the results are expressed as additional increases in cell number compared to 1% FCS alone (at 72 h). Significant increases in cell number were seen with PDGF-BB, bFGF, and EGF (all at a concentration of 20 ng/ml; Table I). Surprisingly, IGF-I and -II at 20 ng/ml (a dose which did not increase [3H]thymidine incorporation) did result in an increase in cell number as seen by counting (Table I).

**Proinflammatory cytokines stimulate proliferation of human colonic myofibroblasts.** IL-β caused a time- and concentration-dependent increase in [3H]thymidine incorporation (Fig. 3a). The peak response was seen at 0.1–1 ng/ml with the response tailing off at higher concentrations and was most marked with a total incubation time of 32 h. The EC₅₀ for the response at 32 h was 15±2 pg/ml (n = 4). At 24 h, a time at which a marked response to PDGF-BB is seen, there was a smaller response in thymidine uptake. At 40 h, [3H]thymidine uptake had declined to a smaller response in thymidine uptake. At 40 h, [3H]thymidine incorporation was still significantly higher than control levels (Fig. 3A).

**Table I. Change in Cell Number in Colonic Myofibroblasts over 72 h**

<table>
<thead>
<tr>
<th>Agonist (20 ng/ml)</th>
<th>Percentage increase in cell number (mean, n = 8) c.f. 1% FCS alone</th>
<th>95% Confidence intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGF</td>
<td>61.9</td>
<td>23.8–100</td>
</tr>
<tr>
<td>bFGF</td>
<td>70.7</td>
<td>29.6–111</td>
</tr>
<tr>
<td>PDGF-BB</td>
<td>55.3</td>
<td>18.9–91.6</td>
</tr>
<tr>
<td>IGF-I</td>
<td>31.1</td>
<td>18.1–44.2</td>
</tr>
<tr>
<td>IGF-II</td>
<td>28.2</td>
<td>13.6–42.8</td>
</tr>
</tbody>
</table>

Changes in cell number in human colonic subepithelial myofibroblasts stimulated with growth factors (all at 20 ng/ml). Cell number was determined by Coulter counting trypsin-harvested cells from 24-well plates (particles > 15 μm) after incubation for 72 h with 1% FCS and with additional growth factors, as indicated. Cell numbers are expressed as a percentage increase over counts obtained from wells containing 1% FCS alone. All data represent mean from eight experiments. Within each experiment, data were pooled from triplicate wells.
incorporation had returned to basal levels over the entire range of concentrations of IL-1β tested (1 pg/ml–10 ng/ml). The effect of IL-1β (32 h) at 0.1 ng/ml was synergistic with that of PDGF-BB (24 h, 20 ng/ml; Fig. 3 b). TNF-α, another proinflammatory cytokine, also produced a dose- and time-dependent increase in [3H]thymidine incorporation, which at 24 h was 1.4±0.2-fold over control (TNF-α = 100 ng/ml) (n = 4, P = 0.049). With agonist present for 32 h, the response was more marked, with a peak of 3.4±0.24-fold at 100 ng/ml (n = 4, P = 0.002), and there was a significant elevation with concentrations as low as 0.1 ng/ml, which was 1.5±0.06-fold over control (n = 4, P = 0.01) (data not shown). IL-6 and -10 induced no significant changes in [3H]thymidine incorporation either at 24, 32, or 40 h over the concentration range tested (0.1–100 ng/ml), a positive control being provided by 10% FCS.

**Figure 3.** Proliferation of human colonic subepithelial myofibroblasts in response to interleukin 1β: dose and time dependence. Significant (*P* < 0.05) increases in [3H]thymidine incorporation were seen with concentrations ≥ 0.01 ng/ml when present for 24 (■) or 32 h (○). After 40 h (□), the levels of [3H]thymidine incorporation had returned to basal (data for positive control of FCS 10% not shown). (b) [3H]thymidine incorporation in response to IL-1β (32 h), PDGF-BB 20 ng/ml (24 h) or both. A marked increase was seen when both agonists were present.

**Table II. Change in Cell Number in Colonic Myofibroblasts over 72 h: Modulation by IL-1β and VIP**

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Percentage increase in cell number (mean, n = 10) c.f. 1% FCS alone</th>
<th>95% Confidence intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDGF-BB (20 ng/ml)</td>
<td>77.6</td>
<td>47–109</td>
</tr>
<tr>
<td>IL-1β (0.1 ng/ml)</td>
<td>18.8</td>
<td>8.2–29</td>
</tr>
<tr>
<td>PDGF + IL-1β</td>
<td>64.4</td>
<td>45–84</td>
</tr>
<tr>
<td>VIP (1 μM)</td>
<td>13.7</td>
<td>–1.6–29.8</td>
</tr>
<tr>
<td>PDGF + VIP</td>
<td>68.2</td>
<td>41.8–97.9</td>
</tr>
</tbody>
</table>

Changes in cell number determined with coulter counting, as described (Table I). PDGF was BB isoform, 20 ng/ml. IL-1β was at 0.1 ng/ml, VIP was 1 μM. Data represent mean of 10 experiments, with triplicate determinations in each, and are expressed relative to control wells containing 1% FCS alone.

Changes in cell number with IL-1β and PDGF-BB were then studied to determine whether the effects on [3H]thymidine incorporation were translated to changes in numbers of cells. Table II shows the results obtained in 10 experiments using PDGF-BB (20 ng/ml), IL-1β (0.1 ng/ml), or both agonists. As before, 1% FCS was included in all wells and the results expressed as percentage increase in cell numbers compared to wells incubated in control medium alone. In these experiments, PDGF-BB produced a significant increase in cell numbers. IL-1β alone produced a small increase in cell numbers that was significant (*P* < 0.05), but when it was added in combination with PDGF-BB, there was a trend towards a decrease in the response compared to PDGF-BB alone. This decrease was not statistically significant.

**VIP opposes proliferative stimuli and elevates intracellular cyclic AMP in human colonic myofibroblasts.** The neuropeptide VIP was investigated to determine its effect on proliferation of myofibroblasts in vitro. The effect of VIP on PDGF-BB–driven proliferation is shown in Fig. 4. VIP at the highest concentration (1 μM) caused no significant reduction in basal [3H]thymidine incorporation. It did, however, cause a significant reduction in the response to PDGF-BB (20 ng/ml for 24 h) when added 10 min before the growth factor. The maximum inhibition of the response to PDGF-BB with 1 μM VIP was 34±7% (n = 12, P = 0.002), and the EC50 for this response was approximately 2.2±0.3 nM (n = 12). Similarly, VIP (1 μM) inhibited the response to IL-1β (0.1 ng/ml added for 32 h) when added 10 min before this agonist by 48±8% (n = 4, P = 0.01). Because one possible mode of action for VIP is through activation of adenylate cyclase, we studied the effect of this agonist on intracellular cyclic AMP production. VIP produced a dose-related increase in cyclic AMP in human colonic myofibroblasts (Fig. 5), the EC50 for this response being 22±9 nM (n = 4). The maximum stimulation observed was 3.4±0.2 over control (n = 4, P = 0.0004). A significant increase in cyclic AMP was seen at concentrations as low as 10 nM, consistent with the data shown for inhibition of [3H]thymidine incorporation in these cells. Finally, we looked for a change in cell numbers using VIP (Table II). VIP (1 μM) alone produced no significant changes in cell numbers, although there was a trend towards an increase. When it was coincubated with PDGF-BB, there was a trend towards a decrease in cell numbers that did not reach significance.

2654 Jobson et al.
thymidine incorporation was seen with VIP 10 nM before the growth factor. A small but not significant decrease in basal PDGF-BB stimulation (20 ng/ml) for 24 h. VIP was added 10 min before PDGF-BB. A dose-related inhibition of the response to PDGF-BB was measured in response to VIP (10 nM) for 30 min. All data are mean ± SEM for 12 experiments (except VIP control [n = 4] and PDGF-BB ± VIP 10^-11 [n = 8]). The mean EC_50 for this response was 2.2 ± 0.3 nM (n = 12).

**Discussion**

In the colon, there is a well recognized population of myofibroblasts resident beneath the basement membrane. Little is known about regulation of cell number in colonic myofibroblasts, but proliferation of similar cells in response to inflammation is seen in other tissues. It is not feasible to study the control of myofibroblast cell number in vivo in humans; hence, for longer term studies on proliferation and/or cell survival, it was necessary to develop an appropriate model. We have, therefore, used primary cultures of human colonic myofibroblasts to study the proliferative response to mediators believed to be important in the pathogenesis of inflammatory bowel disease. These cells exhibit phenotypic features in culture typical of myofibroblasts with actin and vimentin filaments demonstrated by immunofluorescence, and electron and light microscopic features of myofibroblasts.

Initial studies were designed to establish whether peptide growth factors PDGF-BB, bFGF, EGF, IGF-I and -II, which have a potentially important role in the pathogenesis of inflammatory bowel disease, act as mitogens for colonic subepithelial myofibroblasts, and also to determine their relative potency and efficacies. PDGF-BB is widely recognized as a mediator of the inflammatory response and is expressed in human colonic mucosa. In a model of ulcerative colitis in rats, PDGF-BB has been demonstrated to decrease the size and severity of ulcerated lesions and to induce reepithelialization of bFGF expression in many tissues including the human gastrointestinal tract, whereas Satoh and colleagues report that it accelerated the healing of colonic lesions in N-ethylmaleimide–induced colitis in rats. The role for EGF in inflammatory bowel disease is unclear, but it is known to be a trophic factor in the gastrointestinal tract. EGF mRNA is found in both normal and ulcerative colitis colonic biopsies in humans, and EGF enhances resolution of ethanol/trinitrobenzene sulfonic acid–induced colitis in rats when given subcutaneously, whereas it has a protective effect in the same model when administered intraperitoneally. Finally, IGF-I is believed to play an important role in the development of fibrosis in the chronically inflamed intestine. IGF-I stimulates proliferation and collagen production in skin fibroblasts, and insulin (at concentration high enough to activate the IGF receptor) has also been shown to stimulate type III collagen production from fibroblasts derived from Crohn’s disease strictures. In animal models of chronic intestinal inflammation, IGF-I mRNA expression is seen in subepithelial mesenchymal cells in areas of fibrosis, and it is synthesised by macrophages stimulated by proinflammatory cytokines such as IL-1β. In addition, there is upregulation of IGF-I and -II mRNA in specimens obtained from patients with either Crohn’s disease or ulcerative colitis, although, in the latter disease, there seems to be little difference between involved and uninvolved areas. Therefore, there is good evidence that these peptides may be important in either wound repair or fibrotic reactions in the intestine: two key functions of myofibroblasts in disease.

In the studies described here, we found, using [^3H]thymidine incorporation as an index of DNA synthesis, that PDGF-BB had the highest efficacy of all the mitogens tested with a maximum fold-stimulation over control of seven, which was unsurprising given that PDGF-BB is known to be an important mitogen in other myofibroblast-like systems. Although EGF and bFGF had significantly lower maximal responses in our system (i.e., lower efficacies), they were in fact more potent than PDGF-BB. The apparent EC_50 seen with PDGF-BB was 14 ng/ml (0.6 nM), which was similar to that of EGF (2.1 ng/ml ~ 0.4 nM) in these cells but approximately twofold higher than previously reported in human airway smooth muscle.

**Figure 4.** Inhibition of PDGF-BB–driven proliferation by vasoactive intestinal peptide (VIP). [^3H]thymidine incorporation in human colonic subepithelial myofibroblasts was measured in response to PDGF-BB stimulation (20 ng/ml) for 24 h. VIP was added 10 min before the growth factor. A small but not significant decrease in basal thymidine incorporation was seen with VIP 10^-8 M. VIP also caused a dose-related inhibition of the response to PDGF-BB. (P < 0.05 for all concentrations ≥ 10 nM. All data are mean ± SEM for 12 experiments (except VIP control [n = 4] and PDGF-BB ± VIP 10^-11 [n = 8]). The mean EC_50 for this response was 2.2 ± 0.3 nM (n = 12).

**Figure 5.** VIP activates adenylate cyclase. Confluent cells preincubated for 3 h with [^3H]adenine were stimulated with varying concentrations of VIP for 30 min. Reactions were terminated with concentrated HCl and cyclic AMP was extracted using column chromatography. Figure shows conversion of [^3H]adenine to cyclic AMP after stimulation by VIP expressed as fold stimulation over control. The mean EC_50 for this response was 22 ± 9 nM (n = 4).
bFGF was, however, significantly more potent with an EC₀ for stimulation of [³H]thymidine incorporation in colonic myofibroblasts of 2.2 ng/ml (0.13 nM) (P < 0.01 compared with EC₀ for EGF, n = 4). The IGFs had relatively little effect on proliferation except at the highest concentrations, suggesting that they are not important mitogens for these cells.

When these data were compared with changes in cell number, significant discrepancies were noted. At 20 ng/ml, there was no significant difference between PDGF-BB, EGF, and bFGF in their ability to increase cell number. Interestingly, at these doses (at which no increase in thymidine incorporation was seen) both IGF-I and -II caused significant increases in cell number over 72 h. Differences between [³H]thymidine incorporation and other measures of proliferation or cell cycle progression are well recognized. Incomplete mitogens have been characterized (e.g., EGF in porcine aortic smooth muscle cells (37) where the growth factor potently stimulates G₀→ S-phase progression, but does not lead to mitosis) and this phenomenon may in part explain the difference in relative eflicacies of PDGF-BB and EGF, or bFGF at 20 ng/ml when thymidine incorporation is compared with cell number data, if PDGF-BB is acting as a partial mitogen. For IGF-I and -II to produce increases in cell number without changes in thymidine incorporation, an alternative explanation is required. IGF-I may be acting synergistically with other factors present in the medium in the cell number experiments, as 1% FCS was required in these experiments to prevent cell death in the control wells over 72 h. In other smooth muscle cell systems, IGF-I has been reported to act synergistically with bFGF (38), a component of FCS. Alternatively, IGF-I may be acting as a survival factor. There is good evidence (39) that IGF-I protects myofibroblast-like cells from other tissues from undergoing apoptosis and, in our system, there is likely to be a balance between basal proliferation rates and cell death in the presence of 1% FCS. Protecting cells from apoptosis will clearly allow the cell number to increase as proliferation predominates. Further experiments will be necessary to define more precisely which agents inhibit apoptosis by providing a survival signal in this system. It is clear, however, that all the above growth factors increase cell number and, therefore, may be important in wound repair and fibrosis.

We also examined the contribution to myofibroblast proliferation of the potent proinflammatory cytokines TNF-α and IL-1β produced by macrophages in the inflamed colon. There is good evidence that these cytokines mediate inflammatory responses in many tissues and there is evidence for upregulation of TNF-α and IL-1β activity in both ulcerative colitis and Crohn’s disease (8, 9). In other smooth muscle or myofibroblast cell culture models, both these cytokines have been shown to increase DNA synthesis and, in our model, we found similar results, although this was only apparent at longer time-points than the other growth factors studied. IL-1β also produced a significant increase in cell number after an incubation period of 72 h. This would suggest that myofibroblast proliferation is driven by this proinflammatory cytokine. In other models, synergy between IL-1β and growth factors such as PDGF-BB has been seen; for example, IL-1β upregulates PDGF-BB receptor expression leading to enhanced responses to this growth factor (40). The data we obtained with [³H]thymidine incorporation strongly suggest synergy, as the combined effect of the two cytokines is significantly greater than the sum of the two responses when cytokines were added separately. When cell number was examined, however, there was no significant difference between PDGF-BB with IL-1β and PDGF-BB alone. As already discussed, this may be due to discrepancies between entry into S-phase and mitosis, or due to differential effects on cell survival. TNF-α had similar effects to IL-1β on [³H]thymidine incorporation in colonic myofibroblasts. Two other cytokines that are known to be upregulated locally in inflammatory bowel disease (IL-6 and IL-10) were also examined for an effect on DNA synthesis. No increase in [³H]thymidine incorporation was found at a range of concentrations (0.1–100 ng/ml) over incubation periods of 24–40 h, confirming a selective response of myofibroblasts to the proinflammatory ‘master’ cytokines IL-1β and TNF-α.

We next studied the possibility that the mitogenic effects of growth factors may be negatively regulated by VIP. It is unlikely that proliferative stimuli act unopposed in vivo. In myofibroblast-like cells derived from other tissues, agents that elevate cyclic AMP can downregulate responses to proliferative stimuli. One candidate molecule in the colon is VIP, which has been demonstrated to partially inhibit proliferation in human airway smooth muscle cells by a cyclic AMP–dependent mechanism (41). Sources in the colon include both the myenteric plexus, the nerves of which terminate in the lamina propria, and inflammatory cells (15). There appears to be destruction of VIP-containing nerves in the transmural inflammation of Crohn’s disease (42), and it has been reported that there are significant decreases in tissue content of VIP in ulcerative colitis (43). It has been demonstrated, however, that eosinophils derived from inflamed colonic mucosa produce VIP in culture (44). Our data on DNA synthesis would be consistent with the hypothesis that VIP modulates the inflammatory response by restraining myofibroblast proliferation in response to inflammatory mediators, although the effect on cell numbers was small and did not reach significance. One potential mechanism for VIP acting to retard proliferation is via elevation of intracellular cyclic AMP. We have confirmed this action of VIP in colonic myofibroblasts in culture over doses similar to those which inhibit [³H]thymidine incorporation. The possibility that pharmacological manipulation of cell cyclic AMP content could modulate remodeling in the colon during inflammation is worth further study and has clear therapeutic implications.

In conclusion, we have used a novel model system for studying the proliferative responses of human colonic subepithelial myofibroblasts and defined factors that promote proliferation of these cells in vitro. We have used both [³H]thymidine incorporation and Coulter counting to follow changes in cell numbers and have demonstrated that a range of important mediators in the gut can act as mitogens for these cells. We have also demonstrated that these responses may be inhibited by elevation of intracellular cyclic AMP induced by stimulation with VIP. Finally, we have observed discrepancies between DNA synthesis and change in cell number, suggesting that these mediators may also modulate cell survival/apoptosis in addition to their direct effects on mitogenic responses, which will require further investigation.

Acknowledgments

We are grateful to Y.R. Mahida (Division of Gastroenterology, University Hospital, Nottingham) for supplying human colonic subepithelial myofibroblasts used in these studies.

T.M. Jobson is a Wellcome Trust Research Training Fellow. I.P.
Hall is a National Asthma Campaign Senior Fellow. This work was supported by a grant from the Wellcome Trust.

References


